Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Jagsonpal Pharmaceuticals Ltd.
Source DateBoard Meeting DateDetails
20-Apr-2026 27-Apr-2026 Final Dividend & Audited Results
09-Mar-2026 12-Mar-2026 Buy Back of Shares
13-Jan-2026 21-Jan-2026 Quarterly Results
27-Oct-2025 03-Nov-2025 Quarterly Results
23-Jul-2025 26-Jul-2025 Quarterly Results
29-Apr-2025 06-May-2025 Audited Results & Final Dividend
15-Jan-2025 22-Jan-2025 Quarterly Results
16-Oct-2024 23-Oct-2024 Stock Split & Quarterly Results
31-Jul-2024 07-Aug-2024 Quarterly Results
13-May-2024 20-May-2024 Final Dividend & Audited Results
25-Jan-2024 02-Feb-2024 Quarterly Results
26-Oct-2023 03-Nov-2023 Quarterly Results
25-Jul-2023 02-Aug-2023 Quarterly Results
15-May-2023 23-May-2023 Dividend & Audited Results
31-Jan-2023 08-Feb-2023 Quarterly Results
03-Nov-2022 09-Nov-2022 Quarterly Results
04-Aug-2022 09-Aug-2022 Quarterly Results
23-May-2022 30-May-2022 Audited Results & Quarterly Results
04-May-2022 13-May-2022 Inter alia, to consider and approve the alteration in AOA and other routine matters.
03-Feb-2022 11-Feb-2022 Quarterly Results
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Scores| Policies of JFSL
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE| Rights and obligation| SARAL Form
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.